[1] 秦蜀,贺凯,李波,等.乐伐替尼调控VEGFR/NF-κB/R1P2信号治疗原发性肝细胞性肝癌的机制研究[J].东南大学学报(医学版),2019,38(1):84-88.
[2] 韩力,刘琳.靶向VEGF/VEGFR路径治疗肝细胞癌的临床研究进展[J].东南大学学报(医学版),2017,36(2):266-270.
[3] FONTANELLA C,ONGARO E,BOLZONELLO S,et al.Clinical advances in the development of novel VEGFR2 inhibitors[J].Ann Transl Med,2014,2(12):123.
[4] HICKLIN D J,ELLIS L M.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23:1011-1027.
[5] TIAN S,QUAN H,XIE C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci,2011,102(7):1374-1380.
[6] LI J,QIN S,XU J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.
[7] QIN S.Phase Ⅲ study of apatinib in advanced gastric cancer:a randomized,double-blind,placebo-controlled trial[J].J Clin Oncol,2014,32(5):4003.
[8] HUANG L H,WEI Y Y,SHEN S P,et al.Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients[J].Oncotarget,2017,8(17):29346-29354.
[9] SONG Z,YU X,LOU G,et al.Salvage treatment with apatinib for advanced non-small-cell lung cancer[J].Oncol Targets Ther,2017,10:1821-1825.
[10] ZENG D X,WANG C G,LEI W,et al.Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma[J].Oncotarget,2017,8(39):66248-66253.
[11] LUO R H,LI B Q.Clinical effect of apatinib combined with chemotherapy on patients with advanced non-small cell lung cancer after failure of first-line treatment[J].Oncol Pro,2019,17(15):1809-1812.
[12] ZHANG Z H,LUO F,ZHANG Y,et al.Study of apatinib plus gefitinib as first-line therapy in patients with EGFR mutent advenced non-small cell lung cancer[J].Cancer Commun(Lond),2019,39(1):69.
[13] LIN Y,WU Z,ZHANG J,et al.Apatinib for metastatic breast cancerin non-clinical trial setting:satisfying efficacy regardless of previous anti-angiogenic treatment[J/OL].Tumor Biol,2017,39(6):1010428317711033.doi:10.1177/1010428317711033.
[14] KONG Y,SUN L,HOU Z,et al.Apatinib is effective for treatment of advanced hepatocellular carcinoma[J].Oncotarget,2017,8(62):105596-105605.
[15] YU W C,ZHANG K Z,CHEN S G,et al.Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma:a prospective observation study[J].Medicine(Baltimore),2018,97(3):e9704.
[16] LIANG L,WANG L,ZHU P,et al.A pilot study of apatinib as thirdline treatment in patients with heavily treated metastatic colorectal cancer[J].Clin Colorectal Cancer,2018,17(3):e443-e449.
[17] GOU M,SI H,ZHANG Y,et al.Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer:a real-world retrospective study[J].Sci Rep,2018,8(1):4602.
[18] MIAO M,DENG G,LUO S,et al.A phase Ⅱ study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
[19] CHEN K,GAO Y,SHI F,et al.Apatinib-treated advanced medullary thyroid carcinoma:a case report[J].Onco Targets Ther,2018,11:459-463.
[20] FANG S,ZHANG M,WEI G,et al.Apatinib as a third-or further-line treatment in patients with advanced NSCLC harboring wild-type EGFR[J].Oncotarget,2018,9:7175-7181.
[21] 苏贻洲,金泰宇,吴红,等.阿帕替尼致高血压不良反应分析[J].临床合理用药杂志,2018,11(34):13-14.
[22] LI J,ZHAO X,CHEN L,et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer,2010,10(1):529.
[23] 秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015,20(9):841-847.
[24] 马兴群,成远,陈映霞.VEGF信号通路抑制剂相关蛋白尿的研究进展[J].临床肿瘤学杂志,2015,20(4):357-362.
[25] DINCER M,ALTUNDAG K.Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension[J].Ann Pharmacother,2006,40(12):2278-2279.
[26] McLELLAN B,CIARDIELLO F,LACOUTURE M E,et al.Regorafenib associated hand foot skin reaction:practical advice on diagnosis,prevention,and management[J].Ann Oncol,2015,26(10):2017-2026.
[27] BLOCK G A,WHEELER D C,PERSKY M S,et al.Effects of phosphate binders in moderate CKD[J].J Am Soc Nephrol,2012,23(8):1407-1415.
[28] LEE J H,CHUNG Y H,KIM J A,et al.Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma[J].Cancer,2013,119(1):136-142.
[29] MAN X Y,YANG X H,CAI S Q,et al.Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs)and neuropilins (NRPs) on keratinocytes in human epidermis[J].Mol Med,2006,12(7-8):127-136.
[30] 陆凌怡,赖慧颖,鞠强.舒尼替尼致手足皮肤反应1例[J].临床皮肤科杂志,2017,46(2):130-132.
[31] ISAKOVA T,BARCHI-CHUNG A,ENFIELD G,et al.Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD[J].Clin J Am Soc Nephrol,2013,8(6):1009-1018.
[32] ROODHART J M,LANGENBERG M H,WITTEVEEN E,et al.The molecularbasis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway[J].Curr Clin Pharmacol,2008,3(2):132-143.
[33] LI X F,TAN Y N,CAO Y,et al.A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer[J].Medicine (Baltimore),2015,94(39):e1661.
[34] VERHEUL H M,PINEDO H M.Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition[J].Nat Rev Cancer,2007,7(6):475-485.
[35] 邹文,李晓梅,王荣梅.阿帕替尼联合应用替吉奥致严重皮下出血及皮肤破溃1例[J].中国新药与临床杂志,2017,36(3):176-179.
[36] KAMBA T,McDONALD D M.Mechanisms of adverse effects of anti-VEGF therapy for cancer[J].Br J Cancer,2007,96(12):1788-1795.
[37] 石瑶瑶.阿帕替尼治疗恶性肿瘤不良反应的单中心观察性研究[D].济南:山东大学,2017:21-22.
[38] 李元元,刘珏,周庆,等.阿帕替尼致2例严重不良反应分析[J].中国药师,2017,20(11):2037-2038.
[39] 赵成龙,傅昌芳.阿帕替尼致消化道出血[J].世界最新医学信息文摘,2015,15(100):221.
[40] 杨晓瑞,梁明杰,王伟兰.从1例溃疡型胃癌患者上消化道出血探讨抗血管生成药物的安全应用[J].中国药物应用与监测,2016,13(5):280-283. |
